Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Keystone Symposium on Growing to Extremes: Cell Biology and Pathology of Axons
Confounding in association studies: month of birth and multiple sclerosis.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Receptos provides update on progress of lead product candidate RPC1063
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Pharmaceutical approval update.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Sexual dysfunction ın multiple sclerosis: Gender differences.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.

Pages